CGEN

⚡ 1-Minute Take

Data sources: market data, fundamentals, news providers. Data may be delayed.

Key Statistics

📰 Latest News

Compugen Ltd. pioneers immuno-oncology with a diverse pipeline of therapeutic antibodies targeting solid tumors and advanced malignancies, offering a compelling investment opportunity in the high-growth biotechnology sector through strategic collaborations and innovative drug development.

About CGEN

Compugen Ltd. is a clinical-stage therapeutic discovery and development company focused on immuno-oncology. Their pipeline includes multiple Phase I clinical studies for solid tumors and advanced malignancies, positioning them at the forefront of innovative cancer treatments.

Compugen Ltd. Company Overview

Compugen Ltd., founded in 1993 and headquartered in Holon, Israel, is a clinical-stage therapeutic discovery and development company dedicated to researching, developing, and commercializing innovative therapeutic and product candidates. The company focuses primarily on immuno-oncology, leveraging its computational discovery platforms to identify novel drug targets and develop first-in-class therapeutics. Compugen's pipeline includes several programs in Phase I clinical studies, such as COM701, an anti-PVRIG antibody for solid tumors; COM902, a TIGIT-targeting antibody for advanced malignancies; and Bapotulimab, an anti-ILDR2 antibody also for solid tumors. Additionally, AZD2936, a bispecific anti-TIGIT/PD-1 antibody, is in Phase I/II trials for non-small cell lung cancer. These programs reflect the company's commitment to addressing unmet medical needs in cancer treatment. Compugen also has early-stage immuno-oncology programs focused on myeloid targets, further expanding its therapeutic potential. The company has established strategic collaborations with industry leaders like Bayer Pharma AG, Bristol-Myers Squibb, and AstraZeneca, as well as academic institutions like Johns Hopkins School of Medicine, to advance its research and development efforts. These partnerships provide access to resources, expertise, and clinical trial opportunities, enhancing Compugen's ability to bring innovative therapies to market. Compugen operates in Israel, the United States, and Europe, reflecting its global ambitions and reach.

Investment Thesis

Compugen presents a compelling investment opportunity due to its innovative immuno-oncology pipeline and strategic collaborations. The company's focus on novel drug targets, such as PVRIG, TIGIT, and ILDR2, positions it at the forefront of cancer immunotherapy. Positive data from ongoing Phase I clinical trials for COM701, COM902, and Bapotulimab could serve as significant catalysts, driving stock appreciation. The collaboration with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products adds further validation and potential revenue streams. With a market cap of $0.16 billion, Compugen offers significant upside potential if its clinical programs are successful. Key value drivers include the advancement of its pipeline through clinical trials, securing additional partnerships, and ultimately, the commercialization of its therapeutic candidates. Investors should consider the high-risk, high-reward nature of biotechnology investments, but Compugen's innovative approach and strategic partnerships make it an attractive opportunity.

Key Financial Highlights

• Market Cap of $0.16 billion indicates potential for growth if clinical trials are successful.
• Gross Margin of 7.4% reflects the early-stage nature of the company and its focus on R&D.
• Phase I clinical studies ongoing for COM701, COM902, and Bapotulimab, representing key milestones in drug development.
• Collaboration agreements with Bayer Pharma AG, Bristol-Myers Squibb, and AstraZeneca validate the company's technology and provide access to resources.
• Negative P/E ratio of -5.66 reflects the company's current lack of profitability due to heavy investment in research and development.

Industry Context

Compugen operates within the highly competitive biotechnology industry, specifically focusing on immuno-oncology. The market for cancer immunotherapies is experiencing rapid growth, driven by the increasing prevalence of cancer and the demand for more effective and less toxic treatments. Key trends include the development of novel checkpoint inhibitors, combination therapies, and personalized medicine approaches. Compugen's focus on novel targets like PVRIG, TIGIT, and ILDR2 differentiates it from competitors primarily targeting PD-1/PD-L1. Competitors include companies like CRBP, CRDF, CYBN, IPHA, and MIST, each pursuing different approaches to cancer immunotherapy. The industry is characterized by high R&D costs, regulatory hurdles, and intense competition, but also offers significant potential for innovation and financial rewards.

Growth Opportunities

• Advancement of COM701 through Clinical Trials: COM701, an anti-PVRIG antibody, is currently in Phase I clinical study for the treatment of solid tumors. Positive data from these trials could lead to further development and potential commercialization, addressing a significant unmet need in cancer therapy. The market for solid tumor treatments is estimated to be worth billions of dollars, offering a substantial opportunity for Compugen. Timeline: Ongoing Phase I study with potential for Phase II initiation within the next 12-18 months.
• Development of COM902 for Advanced Malignancies: COM902, a therapeutic antibody targeting TIGIT, is in Phase I clinical study in patients with advanced malignancies as a monotherapy. Successful development and commercialization of COM902 could provide a new treatment option for patients with limited alternatives. The market for TIGIT-targeting therapies is expected to grow significantly in the coming years. Timeline: Ongoing Phase I study with potential for further development based on initial results.
• Expansion of Myeloid-Focused Immuno-Oncology Programs: Compugen has early-stage immuno-oncology programs focused primarily on myeloid targets. These programs represent a novel approach to cancer immunotherapy and could lead to the discovery of new therapeutic targets and drug candidates. The market for myeloid-targeting therapies is still emerging, offering a first-mover advantage for Compugen. Timeline: Preclinical development with potential for clinical trials in the next 2-3 years.
• Leveraging Strategic Collaborations for Drug Development: Compugen has established collaborations with Bayer Pharma AG, Bristol-Myers Squibb, and AstraZeneca to advance its research and development efforts. These partnerships provide access to resources, expertise, and clinical trial opportunities, accelerating the development of its pipeline. The potential for milestone payments and royalties from these collaborations represents a significant growth driver. Timeline: Ongoing collaborations with potential for new partnerships in the future.
• Commercialization of AZD2936 for Non-Small Cell Lung Cancer: AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Successful development and commercialization of AZD2936 could provide a new treatment option for patients with this disease. The market for non-small cell lung cancer therapies is substantial, offering a significant opportunity for Compugen. Timeline: Ongoing Phase I/II study with potential for further development based on initial results.

Competitive Advantages

• Proprietary computational discovery platforms for identifying novel drug targets.
• Strong intellectual property portfolio protecting its therapeutic candidates.
• Strategic collaborations with leading pharmaceutical companies and academic institutions.
• First-mover advantage in targeting novel immune checkpoint regulators like PVRIG, TIGIT, and ILDR2.

Strengths

• Innovative immuno-oncology pipeline targeting novel immune checkpoints.
• Strategic collaborations with leading pharmaceutical companies.
• Proprietary computational discovery platforms.
• Experienced management team with expertise in drug development.

Weaknesses

• Limited financial resources compared to larger pharmaceutical companies.
• High dependence on clinical trial outcomes.
• Lack of commercialized products and revenue streams.
• High cash burn rate due to R&D expenses.

Opportunities

• Expansion of pipeline through internal discovery and external collaborations.
• Advancement of clinical programs to later stages of development.
• Securing regulatory approvals and commercializing therapeutic products.
• Potential for milestone payments and royalties from collaborations.

Threats

• Clinical trial failures and regulatory setbacks.
• Competition from other immuno-oncology companies.
• Patent challenges and intellectual property disputes.
• Changes in healthcare regulations and reimbursement policies.

What CGEN Does

• Researches and develops therapeutic candidates for cancer immunotherapy.
• Focuses on discovering novel drug targets using computational biology.
• Develops antibody-based therapeutics targeting immune checkpoint regulators.
• Conducts Phase I and Phase I/II clinical trials for various cancer treatments.
• Collaborates with pharmaceutical companies and academic institutions to advance drug development.
• Commercializes therapeutic products in Israel, the United States, and Europe.

Business Model

• Develops and out-licenses therapeutic candidates to pharmaceutical companies.
• Generates revenue through collaboration agreements, milestone payments, and royalties.
• Focuses on early-stage drug discovery and clinical development.
• Partners with larger pharmaceutical companies for late-stage development and commercialization.

Key Customers

• Pharmaceutical companies seeking innovative cancer therapies.
• Patients with solid tumors and advanced malignancies.
• Academic institutions and research organizations.
• Healthcare providers and hospitals.

Competitors

• Corvus Pharmaceuticals Inc (CRBP): Focuses on developing small molecule and antibody therapies for cancer.
• Cardiff Oncology Inc (CRDF): Developing therapies targeting replication stress in cancer cells.
• Cybin Inc. (CYBN): Focuses on psychedelic drug development for mental health conditions.
• Invesco International Developed Growth ETF (IPHA): Provides diversified exposure to developed market equities.
• Milestone Pharmaceuticals Inc (MIST): Developing therapies for cardiovascular diseases.

Catalysts

• Upcoming: Data readouts from Phase I clinical trials for COM701, COM902, and Bapotulimab.
• Ongoing: Enrollment and progress in Phase I/II clinical study of AZD2936.
• Ongoing: Potential for new collaboration agreements with pharmaceutical companies.
• Ongoing: Advancement of early-stage immuno-oncology programs focused on myeloid targets.

Risks

• Potential: Clinical trial failures or delays could negatively impact stock price.
• Potential: Regulatory hurdles and delays in obtaining marketing approvals.
• Ongoing: Competition from other companies developing immuno-oncology therapies.
• Ongoing: Dependence on collaboration partners for funding and development support.
• Ongoing: High cash burn rate and need for additional financing.

FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Related Stocks in Biotechnology

Browse More

Next Steps